LivaNova PLC Research and Development Expense
LivaNova PLC (LIVN) reported Research and Development Expense of $53.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- LivaNova PLC research and development expense for the quarter ending 2026-06-30 was $53.66M, a 13.73% increase year-over-year.
- LivaNova PLC research and development expense for the quarter ending 2026-03-31 was $58.70M, a 54.95% increase year-over-year.
- LivaNova PLC research and development expense for the quarter ending 2025-12-31 was $52.12M, a 20.35% increase year-over-year.
- LivaNova PLC research and development expense for the quarter ending 2025-09-30 was $48.58M, a 0.47% decline year-over-year.
- LivaNova PLC research and development expense for fiscal 2025 was $185.76M, a 1.78% increase from fiscal 2024.
- LivaNova PLC research and development expense for fiscal 2024 was $182.51M, a 5.83% decline from fiscal 2023.
- LivaNova PLC research and development expense for fiscal 2023 was $193.82M, a 24.40% increase from fiscal 2022.
- LivaNova PLC research and development expense for fiscal 2022 was $155.81M, a 15.05% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 7 month | Research and Development Expense 8 month | Research and Development Expense 8 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $53.66M 10-Q · filed 2026-08-05 | $112.36M 10-Q · filed 2026-08-05 | $164.48M derived: sum of 3 quarters · filed 2026-08-05 | $213.06M derived: sum of 4 quarters · filed 2026-08-05 | |||||||
| 2026-03-31 | $58.70M 10-Q · filed 2026-05-06 | $110.82M derived: sum of 2 quarters · filed 2026-05-06 | $159.40M derived: sum of 3 quarters · filed 2026-05-06 | $206.58M derived: sum of 4 quarters · filed 2026-08-05 | |||||||
| 2025-12-31 | $52.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $100.70M derived: sum of 2 quarters · filed 2026-02-25 | $147.88M derived: sum of 3 quarters · filed 2026-08-05 | $185.76M 10-K · filed 2026-02-25 | |||||||
| 2025-09-30 | $48.58M 10-Q · filed 2025-11-05 | $95.76M derived: sum of 2 quarters · filed 2026-08-05 | $133.64M 10-Q · filed 2025-11-05 | $176.95M derived: sum of 4 quarters · filed 2026-08-05 | |||||||
| 2025-06-30 | $47.19M 10-Q · filed 2026-08-05 | $85.06M 10-Q · filed 2026-08-05 | $128.37M derived: sum of 3 quarters · filed 2026-08-05 | $177.18M derived: sum of 4 quarters · filed 2026-08-05 | |||||||
| 2025-03-31 | $37.88M 10-Q · filed 2026-05-06 | $81.19M derived: sum of 2 quarters · filed 2026-05-06 | $129.99M derived: sum of 3 quarters · filed 2026-05-06 | $174.73M derived: sum of 4 quarters · filed 2026-05-06 | |||||||
| 2024-12-31 | $43.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $92.11M derived: sum of 2 quarters · filed 2026-02-25 | $136.85M derived: sum of 3 quarters · filed 2026-02-25 | $182.51M 10-K · filed 2026-02-25 | |||||||
| 2024-09-30 | $48.80M 10-Q · filed 2025-11-05 | $93.54M derived: sum of 2 quarters · filed 2025-11-05 | $139.21M 10-Q · filed 2025-11-05 | $185.37M derived: sum of 4 quarters · filed 2026-02-25 | |||||||
| 2024-06-30 | $44.74M 10-Q · filed 2025-08-06 | $90.40M 10-Q · filed 2025-08-06 | $136.57M derived: sum of 3 quarters · filed 2026-02-25 | $183.11M derived: sum of 4 quarters · filed 2026-02-25 | |||||||
| 2024-03-31 | $45.66M 10-Q · filed 2025-05-07 | $91.83M derived: sum of 2 quarters · filed 2026-02-25 | $138.37M derived: sum of 3 quarters · filed 2026-02-25 | $189.50M derived: sum of 4 quarters · filed 2026-02-25 | |||||||
| 2023-12-31 | $46.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $92.71M derived: sum of 2 quarters · filed 2026-02-25 | $143.83M derived: sum of 3 quarters · filed 2026-02-25 | $193.82M 10-K · filed 2026-02-25 | |||||||
| 2023-09-30 | $46.54M 10-Q · filed 2024-10-31 | $97.67M derived: sum of 2 quarters · filed 2024-10-31 | $147.65M 10-Q · filed 2024-10-31 | $192.58M derived: sum of 4 quarters · filed 2025-02-25 | |||||||
| 2023-06-30 | $51.12M 10-Q · filed 2024-08-01 | $101.11M 10-Q · filed 2024-08-01 | $146.04M derived: sum of 3 quarters · filed 2025-02-25 | $181.77M derived: sum of 4 quarters · filed 2025-02-25 | |||||||
| 2023-03-31 | $49.99M 10-Q · filed 2024-05-03 | $94.92M derived: sum of 2 quarters · filed 2025-02-25 | $130.64M derived: sum of 3 quarters · filed 2025-02-25 | $164.87M derived: sum of 4 quarters · filed 2025-02-25 | |||||||
| 2022-12-31 | $44.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $80.66M derived: sum of 2 quarters · filed 2025-02-25 | $114.89M derived: sum of 3 quarters · filed 2025-02-25 | $155.81M 10-K · filed 2025-02-25 | |||||||
| 2022-09-30 | $35.73M 10-Q · filed 2023-11-01 | $69.95M derived: sum of 2 quarters · filed 2023-11-01 | $110.87M 10-Q · filed 2023-11-01 | $154.97M derived: sum of 4 quarters · filed 2024-02-29 | |||||||
| 2022-06-30 | $34.23M 10-Q · filed 2023-07-26 | $75.15M 10-Q · filed 2023-07-26 | $119.25M derived: sum of 3 quarters · filed 2024-02-29 | $161.38M derived: sum of 4 quarters · filed 2024-02-29 | |||||||
| 2022-03-31 | $40.92M 10-Q · filed 2023-05-03 | $85.02M derived: sum of 2 quarters · filed 2024-02-29 | $127.15M derived: sum of 3 quarters · filed 2024-02-29 | $179.71M derived: sum of 4 quarters · filed 2024-02-29 | |||||||
| 2021-12-31 | $44.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $86.23M derived: sum of 2 quarters · filed 2024-02-29 | $138.79M derived: sum of 3 quarters · filed 2024-02-29 | $183.41M 10-K · filed 2024-02-29 | |||||||
| 2021-09-30 | $42.13M 10-Q · filed 2022-11-02 | $94.69M derived: sum of 2 quarters · filed 2022-11-02 | $139.31M 10-Q · filed 2022-11-02 | $183.79M derived: sum of 4 quarters · filed 2023-02-27 | |||||||
| 2021-06-30 | $52.56M 10-Q · filed 2022-08-03 | $97.18M 10-Q · filed 2022-08-03 | $141.66M derived: sum of 3 quarters · filed 2023-02-27 | $189.03M derived: sum of 4 quarters · filed 2023-02-27 | |||||||
| 2021-03-31 | $44.63M 10-Q · filed 2022-05-04 | $89.11M derived: sum of 2 quarters · filed 2023-02-27 | $136.47M derived: sum of 3 quarters · filed 2023-02-27 | $161.63M derived: sum of 4 quarters · filed 2023-02-27 | |||||||
| 2020-12-31 | $44.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $91.85M derived: sum of 2 quarters · filed 2023-02-27 | $117.00M derived: sum of 3 quarters · filed 2023-02-27 | $152.90M 10-K · filed 2023-02-27 | |||||||
| 2020-09-30 | $47.37M 10-Q · filed 2021-11-03 | $72.52M derived: sum of 2 quarters · filed 2021-11-03 | $108.42M 10-Q · filed 2021-11-03 | $131.25M derived: sum of 4 quarters · filed 2022-03-01 | |||||||
| 2020-06-30 | $25.15M 10-Q · filed 2021-07-28 | $61.05M 10-Q · filed 2021-07-28 | $83.88M derived: sum of 3 quarters · filed 2022-03-01 | $129.78M derived: sum of 4 quarters · filed 2022-03-01 | |||||||
| 2020-03-31 | $35.90M 10-Q · filed 2021-04-28 | $58.73M derived: sum of 2 quarters · filed 2022-03-01 | $104.63M derived: sum of 3 quarters · filed 2022-03-01 | $139.18M derived: sum of 4 quarters · filed 2022-03-01 | |||||||
| 2019-12-31 | $22.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $68.73M derived: sum of 2 quarters · filed 2022-03-01 | $103.27M derived: sum of 3 quarters · filed 2022-03-01 | $146.85M 10-K · filed 2022-03-01 | $149.89M 10-K · filed 2020-03-02 | ||||||
| 2019-09-30 | $45.90M 10-Q · filed 2020-10-29 | $80.45M derived: sum of 2 quarters · filed 2020-10-29 | $124.02M 10-Q · filed 2020-10-29 | $161.59M derived: sum of 4 quarters · filed 2021-03-01 | |||||||
| 2019-06-30 | $34.54M 10-Q · filed 2020-07-29 | $78.12M 10-Q · filed 2020-07-29 | $115.68M derived: sum of 3 quarters · filed 2021-03-01 | $158.10M derived: sum of 4 quarters · filed 2021-03-01 | |||||||
| 2019-03-31 | $43.58M 10-Q · filed 2020-04-30 | $81.14M derived: sum of 2 quarters · filed 2021-03-01 | $123.56M derived: sum of 3 quarters · filed 2021-03-01 | $157.77M derived: sum of 4 quarters · filed 2021-03-01 | |||||||
| 2018-12-31 | $37.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $79.98M derived: sum of 2 quarters · filed 2021-03-01 | $114.20M derived: sum of 3 quarters · filed 2021-03-01 | $145.95M 10-K · filed 2021-03-01 | $146.02M 10-K · filed 2019-03-18 | ||||||
| 2018-09-30 | $42.42M 10-Q · filed 2019-10-30 | $76.63M derived: sum of 2 quarters · filed 2019-10-30 | $108.38M 10-Q · filed 2019-10-30 | $140.78M derived: sum of 4 quarters · filed 2020-03-02 | |||||||
| 2018-06-30 | $34.22M 10-Q · filed 2019-07-31 | $65.97M 10-Q · filed 2019-07-31 | $98.36M derived: sum of 3 quarters · filed 2020-03-02 | $121.26M derived: sum of 4 quarters · filed 2020-03-02 | |||||||
| 2018-03-31 | $31.75M 10-Q · filed 2019-05-01 | $64.15M derived: sum of 2 quarters · filed 2020-03-02 | $87.05M derived: sum of 3 quarters · filed 2020-03-02 | $120.88M derived: sum of 4 quarters · filed 2020-03-02 | |||||||
| 2017-12-31 | $32.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $55.30M derived: sum of 2 quarters · filed 2020-03-02 | $89.13M derived: sum of 3 quarters · filed 2020-03-02 | $109.52M 10-K · filed 2020-03-02 | $109.66M 10-K · filed 2018-02-28 | ||||||
| 2017-09-30 | $22.90M 10-Q · filed 2018-11-01 | $31.39M 10-Q · filed 2017-11-02 | $56.74M derived: sum of 2 quarters · filed 2018-11-01 | $77.12M 10-Q · filed 2018-11-01 | $104.05M 10-Q · filed 2017-11-02 | $65.12M derived: sum of 4 quarters · filed 2019-03-18 | |||||
| 2017-06-30 | $33.83M 10-Q · filed 2018-08-02 | $43.01M 10-Q · filed 2017-08-09 | $54.22M 10-Q · filed 2018-08-02 | $72.66M 10-Q · filed 2017-08-09 | $42.22M derived: sum of 3 quarters · filed 2019-03-18 | $74.40M derived: sum of 4 quarters · filed 2019-03-18 | |||||
| 2017-03-31 | $20.39M 10-Q · filed 2018-05-03 | $29.65M 10-Q · filed 2017-05-03 | $8.39M derived: sum of 2 quarters · filed 2019-03-18 | $40.56M derived: sum of 3 quarters · filed 2019-03-18 | $70.77M derived: sum of 4 quarters · filed 2019-03-18 | ||||||
| 2016-12-31 | -$12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $20.18M derived: sum of 2 quarters · filed 2019-03-18 | $50.39M derived: sum of 3 quarters · filed 2019-03-18 | $82.08M 10-K · filed 2019-03-18 | $122.45M 10-K · filed 2017-03-01 | ||||||
| 2016-09-30 | $32.17M 10-Q · filed 2017-11-02 | $62.39M derived: sum of 2 quarters · filed 2017-11-02 | $94.08M 10-Q · filed 2017-11-02 | ||||||||
| 2016-06-30 | $30.21M 10-Q · filed 2017-08-09 | $61.90M 10-Q · filed 2017-08-09 | |||||||||
| 2016-03-31 | $31.69M 10-Q · filed 2017-05-03 | ||||||||||
| 2015-12-31 | $41.92M 10-K · filed 2018-02-28 | $51.93M 10-KT · filed 2016-03-04 | |||||||||
| 2015-10-18 | $14.74M 10-Q · filed 2016-11-02 | $15.25M 10-Q · filed 2015-12-02 | $25.31M 10-Q · filed 2015-12-08 | $35.23M 10-Q · filed 2016-11-02 | |||||||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-06 | $0.00 10-Q · filed 2015-11-06 | |||||||||
| 2015-07-24 | $9.80M 10-Q · filed 2016-08-05 | $20.49M 10-Q · filed 2016-08-05 | |||||||||
| 2015-04-24 | $10.69M 10-Q · filed 2016-05-09 | $42.24M 10-K · filed 2018-02-28 | $43.28M 10-KT · filed 2016-03-04 | ||||||||
| 2014-12-26 | $28.13M 10-K · filed 2018-02-28 | ||||||||||
| 2014-10-24 | $10.82M 10-Q · filed 2015-12-08 | $21.38M 10-Q · filed 2015-12-08 | |||||||||
| 2014-04-25 | $45.22M 10-K · filed 2017-03-01 | $46.56M 10-KT · filed 2016-03-04 | |||||||||
| 2013-04-26 | $41.55M 10-KT · filed 2016-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |